114 related articles for article (PubMed ID: 30737978)
1. Enabled homolog shown to be a potential biomarker and prognostic indicator for breast cancer by bioinformatics analysis.
Li QL; Su YL; Zeng M; Shen WX
Clin Invest Med; 2019 Jan; 41(4):E186-E195. PubMed ID: 30737978
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics analysis of prognostic significance of COL10A1 in breast cancer.
Zhang M; Chen H; Wang M; Bai F; Wu K
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32043519
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of PBX1 and EMP2 as Prognostic Biomarkers in Estrogen Receptor-Negative Breast Cancer via Data Mining.
Qiu Y; Lu G; Wu Y
J Comput Biol; 2020 Oct; 27(10):1509-1518. PubMed ID: 32216630
[TBL] [Abstract][Full Text] [Related]
4. Enah overexpression is correlated with poor survival and aggressive phenotype in gastric cancer.
Chen D; Xu L; Li X; Chu Y; Jiang M; Xu B; Zhao M; Wang W; Wang H; Kang H; Wang K; Wu K; Liang J; Ren G
Cell Death Dis; 2018 Sep; 9(10):998. PubMed ID: 30250066
[TBL] [Abstract][Full Text] [Related]
5. The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma.
Wu HT; Liu J; Li GW; Shen JX; Huang YT
Oncotarget; 2017 May; 8(22):36279-36288. PubMed ID: 28422733
[TBL] [Abstract][Full Text] [Related]
6. Prognostic values of the inhibitor of DNA‑binding family members in breast cancer.
Zhou XL; Zeng D; Ye YH; Sun SM; Lu XF; Liang WQ; Chen CF; Lin HY
Oncol Rep; 2018 Oct; 40(4):1897-1906. PubMed ID: 30066902
[TBL] [Abstract][Full Text] [Related]
7. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
8. Identification of prognostic significance of BIRC5 in breast cancer using integrative bioinformatics analysis.
Dai JB; Zhu B; Lin WJ; Gao HY; Dai H; Zheng L; Shi WH; Chen WX
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32043523
[TBL] [Abstract][Full Text] [Related]
9. Expression of Protein 4.1 Family in Breast Cancer: Database Mining for 4.1 Family Members in Malignancies.
Feng G; Guo K; Yan Q; Ye Y; Shen M; Ruan S; Qiu S
Med Sci Monit; 2019 May; 25():3374-3389. PubMed ID: 31063460
[TBL] [Abstract][Full Text] [Related]
10. Identification of NCAPH as a biomarker for prognosis of breast cancer.
Lu H; Shi C; Wang S; Yang C; Wan X; Luo Y; Tian L; Li L
Mol Biol Rep; 2020 Oct; 47(10):7831-7842. PubMed ID: 33009967
[TBL] [Abstract][Full Text] [Related]
11. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
Di Modugno F; DeMonte L; Balsamo M; Bronzi G; Nicotra MR; Alessio M; Jager E; Condeelis JS; Santoni A; Natali PG; Nisticò P
Cancer Res; 2007 Mar; 67(6):2657-65. PubMed ID: 17363586
[TBL] [Abstract][Full Text] [Related]
12. Identification of Potential Therapeutic Targets Among CXC Chemokines in Breast Tumor Microenvironment Using Integrative Bioinformatics Analysis.
Chen E; Qin X; Peng K; Xu X; Li W; Cheng X; Tang C; Cui Y; Wang Z; Liu T
Cell Physiol Biochem; 2018; 45(5):1731-1746. PubMed ID: 29495008
[TBL] [Abstract][Full Text] [Related]
13. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
Di Modugno F; Mottolese M; Di Benedetto A; Conidi A; Novelli F; Perracchio L; Venturo I; Botti C; Jager E; Santoni A; Natali PG; Nisticò P
Clin Cancer Res; 2006 Mar; 12(5):1470-8. PubMed ID: 16533770
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
15. Bioinformatics analysis of prognostic value of
Chen WX; Cheng L; Xu LY; Qian Q; Zhu YL
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30837324
[No Abstract] [Full Text] [Related]
16. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
[TBL] [Abstract][Full Text] [Related]
17. Rab22a is a novel prognostic marker for cell progression in breast cancer.
He M; Shen L; Jiang C; Gao G; Wang K; Jiao Y; Sun L; Cui Y; Ke Z; Yang Z
Int J Mol Med; 2020 Apr; 45(4):1037-1046. PubMed ID: 32124943
[TBL] [Abstract][Full Text] [Related]
18. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
19. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients.
Maciejczyk A; Łacko A; Ekiert M; Jagoda E; Wysocka T; Matkowski R; Hałoń A; Györffy B; Lage H; Surowiak P
Histol Histopathol; 2013 Apr; 28(4):513-24. PubMed ID: 23364898
[TBL] [Abstract][Full Text] [Related]
20. CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma.
Wu J
Cancer Biomark; 2020; 29(1):89-99. PubMed ID: 32568178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
